Evidence map›Paper›PMID 31288852›Full record

ArticleActa neuropathologica communications2019

An unusual recurrent high-grade glioneuronal tumor with MAP2K1 mutation and CDKN2A/B homozygous deletion.

Barry Cheaney, Stephen Bowden, Katie Krause, Emily A Sloan, Arie Perry, David A Solomon, Seunggu Jude Han, Matthew D Wood

Open access · goldAbstract readCase ReportsLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropathologica communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Barry CheaneySchool of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
Stephen BowdenDepartment of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA.
Katie KrauseDepartment of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA.
Emily A SloanDepartment of Pathology, University of California San Francisco, San Francisco, California, USA.
Arie PerryDepartment of Pathology, University of California San Francisco, San Francisco, California, USA.
David A SolomonDepartment of Pathology, University of California San Francisco, San Francisco, California, USA.
Seunggu Jude HanDepartment of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA.
Matthew D WoodDepartment of Pathology, Oregon Health & Science University, Mail Code L-113, 3181 SW Sam Jackson Park Road, Portland, OR, 97202, USA. woodmat@OHSU.edu.ORCID 0000-0002-2385-8128
Oregon Health & Science University · USUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedBrain NeoplasmsCyclin-Dependent Kinase Inhibitor p15Cyclin-Dependent Kinase Inhibitor p16GangliogliomaGene DeletionHomozygoteHumansMaleMAP Kinase Kinase 1MutationNeoplasm GradingNeoplasm Recurrence, LocalCDKN2A protein, humanCDKN2B protein, humanCyclin-Dependent Kinase Inhibitor p15Cyclin-Dependent Kinase Inhibitor p16MAP2K1 protein, humanMAP Kinase Kinase 1AnaplasticCDKN2A/B homozygous deletionGlioneuronal tumorMAP2K1 mutationMultinodular and vacuolating neuronal tumor of the cerebrumNext-generation sequencing

Identifiers

PMID31288852
PMCPMC6617605
OpenAlexW2957446190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.